Roche Acquires 89bio for $3.5 Billion to Address Obesity-Related Diseases
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 18 2025
0mins
Should l Buy ?
Source: Yahoo Finance
Acquisition Announcement: Roche has agreed to acquire the small biotech company 89bio, which specializes in the MASH drug, in a deal valued at up to $3.5 billion.
Market Reaction: Following the announcement, 89bio's stock price nearly doubled, reflecting positive investor sentiment regarding the acquisition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
